share_log

Truist Securities Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $7

Truist Securities Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $7

Truist Securities維持對Sangamo Therapeutics的買入,將目標股價下
Benzinga ·  2023/08/15 10:37

Truist Securities analyst Nicole Germino maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and lowers the price target from $8 to $7.

Truist Securities分析師妮可·傑爾米諾維持Sangamo Therapeutics(納斯達克股票代碼:SGMO)的買入,並將目標股價從8美元下調至7美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論